Mark A Jenkins1, James G Dowty2, Driss Ait Ouakrim2, John D Mathews2, John L Hopper2, Youenn Drouet2, Christine Lasset2, Valérie Bonadona2, Aung Ko Win2. 1. Mark A. Jenkins, James G. Dowty, Driss Ait Ouakrim, John D. Mathews, John L. Hopper, and Aung Ko Win, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; John L. Hopper, Institute of Health and Environment, School of Public Health, Seoul National University, Seoul, Korea; Youenn Drouet, Christine Lasset, and Valérie Bonadona, Université Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5558 Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne; and Youenn Drouet, Christine Lasset, and Valérie Bonadona, Centre Léon Bérard, Lyon, France. m.jenkins@unimelb.edu.au. 2. Mark A. Jenkins, James G. Dowty, Driss Ait Ouakrim, John D. Mathews, John L. Hopper, and Aung Ko Win, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; John L. Hopper, Institute of Health and Environment, School of Public Health, Seoul National University, Seoul, Korea; Youenn Drouet, Christine Lasset, and Valérie Bonadona, Université Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5558 Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne; and Youenn Drouet, Christine Lasset, and Valérie Bonadona, Centre Léon Bérard, Lyon, France.
Abstract
PURPOSE: For carriers of germline mutations in DNA mismatch repair genes, the most relevant statistic for cancer prevention is colorectal cancer (Lynch syndrome) risk, particularly in the short term. METHODS: We conducted a meta-analysis of all independent published Lynch syndrome studies reporting age- and sex-dependent colorectal cancer risks. We estimated 5-year colorectal cancer risk over different age groups, separately for male and female mutation carriers, and number needed to screen to prevent one death. RESULTS: We pooled estimates from analyses of 1,114 Lynch syndrome families (508 with MLH1 mutations and 606 with MSH2 mutations). On average, one in 71 male and one in 102 female MLH1 or MSH2 mutation carriers in their 20s will be diagnosed with colorectal cancer in the next 5 years. These colorectal cancer risks increase with age, peaking in the 50s (one in seven males and one in 12 females), and then decrease with age (one in 13 males and one in 19 females in their 70s). Annual colonoscopy in 16 males or 25 females in their 50s would prevent one death from colorectal cancer over 5 years while resulting in almost no serious complications. In comparison, annual colonoscopy in 155 males or 217 females in their 20s would prevent one death while resulting in approximately one serious complication. CONCLUSION: For MLH1 or MSH2 mutation carriers, current guidelines recommend colonoscopy every 1 to 2 years starting in their 20s. Our findings support this regimen from age 30 years; however, it might not be justifiable for carriers who are in their 20s.
PURPOSE: For carriers of germline mutations in DNA mismatch repair genes, the most relevant statistic for cancer prevention is colorectal cancer (Lynch syndrome) risk, particularly in the short term. METHODS: We conducted a meta-analysis of all independent published Lynch syndrome studies reporting age- and sex-dependent colorectal cancer risks. We estimated 5-year colorectal cancer risk over different age groups, separately for male and female mutation carriers, and number needed to screen to prevent one death. RESULTS: We pooled estimates from analyses of 1,114 Lynch syndrome families (508 with MLH1 mutations and 606 with MSH2 mutations). On average, one in 71 male and one in 102 female MLH1 or MSH2 mutation carriers in their 20s will be diagnosed with colorectal cancer in the next 5 years. These colorectal cancer risks increase with age, peaking in the 50s (one in seven males and one in 12 females), and then decrease with age (one in 13 males and one in 19 females in their 70s). Annual colonoscopy in 16 males or 25 females in their 50s would prevent one death from colorectal cancer over 5 years while resulting in almost no serious complications. In comparison, annual colonoscopy in 155 males or 217 females in their 20s would prevent one death while resulting in approximately one serious complication. CONCLUSION: For MLH1 or MSH2 mutation carriers, current guidelines recommend colonoscopy every 1 to 2 years starting in their 20s. Our findings support this regimen from age 30 years; however, it might not be justifiable for carriers who are in their 20s.
Authors: Zhengyi Deng; Kanhua Yin; Yujia Bao; Victor Diego Armengol; Cathy Wang; Ankur Tiwari; Regina Barzilay; Giovanni Parmigiani; Danielle Braun; Kevin S Hughes Journal: JCO Clin Cancer Inform Date: 2019-08
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: Pål Møller; Toni Seppälä; Inge Bernstein; Elke Holinski-Feder; Paola Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf Sijmons; Jacqueline Jeffries; Hans Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul Wijnen; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Julian R Sampson; Gabriel Capella; Jukka-Pekka Mecklin; Gabriela Möslein Journal: Gut Date: 2015-12-09 Impact factor: 23.059
Authors: S Ghazaleh Dashti; Aung Ko Win; Sheetal S Hardikar; Stephen E Glombicki; Sheila Mallenahalli; Selvi Thirumurthi; Susan K Peterson; Y Nancy You; Daniel D Buchanan; Jane C Figueiredo; Peter T Campbell; Steven Gallinger; Polly A Newcomb; John D Potter; Noralane M Lindor; Loic Le Marchand; Robert W Haile; John L Hopper; Mark A Jenkins; Karen M Basen-Engquist; Patrick M Lynch; Mala Pande Journal: Int J Cancer Date: 2018-08-07 Impact factor: 7.316